Research programme: allergic respiratory disease therapeutics - Protectimmun
Latest Information Update: 14 Sep 2023
Price :
$50 *
At a glance
- Originator Protectimmun
- Class Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Allergic asthma
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Allergic asthma in Germany (unspecified route) (Protectimmun pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Allergic-asthma in Germany
- 05 Aug 2016 Preclinical trials in Allergic asthma in Germany (unspecified route)